1. Home
  2. WAT vs KVUE Comparison

WAT vs KVUE Comparison

Compare WAT & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waters Corporation

WAT

Waters Corporation

HOLD

Current Price

$341.82

Market Cap

33.5B

Sector

Industrials

ML Signal

HOLD

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$17.58

Market Cap

32.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAT
KVUE
Founded
1958
2022
Country
United States
United States
Employees
7900
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Specialty Chemicals
Sector
Industrials
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
33.5B
32.9B
IPO Year
1996
2023

Fundamental Metrics

Financial Performance
Metric
WAT
KVUE
Price
$341.82
$17.58
Analyst Decision
Buy
Buy
Analyst Count
17
11
Target Price
$379.19
$19.45
AVG Volume (30 Days)
1.1M
17.6M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
4.82%
EPS Growth
0.47
40.74
EPS
N/A
0.25
Revenue
N/A
$15,124,000,000.00
Revenue This Year
$104.66
$4.85
Revenue Next Year
$10.40
$2.63
P/E Ratio
N/A
$69.98
Revenue Growth
N/A
N/A
52 Week Low
$275.05
$14.02
52 Week High
$414.15
$24.00

Technical Indicators

Market Signals
Indicator
WAT
KVUE
Relative Strength Index (RSI) 57.91 54.07
Support Level $340.09 $16.89
Resistance Level $356.41 $17.85
Average True Range (ATR) 11.97 0.34
MACD -0.03 0.02
Stochastic Oscillator 53.79 62.84

Price Performance

Historical Comparison
WAT
KVUE

About WAT Waters Corporation

Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

Share on Social Networks: